GETINGE AB/ADR (OTCMKTS:GNGBY) and 21st North (OTCMKTS:ULGX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.
This is a summary of current ratings and recommmendations for GETINGE AB/ADR and 21st North, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GETINGE AB/ADR pays an annual dividend of $0.12 per share and has a dividend yield of 1.3%. 21st North does not pay a dividend.
Earnings & Valuation
This table compares GETINGE AB/ADR and 21st North’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GETINGE AB/ADR||$5.27 billion||0.45||$161.40 million||N/A||N/A|
GETINGE AB/ADR has higher revenue and earnings than 21st North.
Institutional and Insider Ownership
0.0% of GETINGE AB/ADR shares are owned by institutional investors. Comparatively, 0.2% of 21st North shares are owned by institutional investors. 8.5% of 21st North shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares GETINGE AB/ADR and 21st North’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
GETINGE AB/ADR has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, 21st North has a beta of 5.99, suggesting that its share price is 499% more volatile than the S&P 500.
GETINGE AB/ADR beats 21st North on 5 of the 8 factors compared between the two stocks.
About GETINGE AB/ADR
Getinge AB provides solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Surgical Workflows, and Life Science segments. It offers anesthesia systems, acute care ventilation and hemodynamic monitoring, covered stents, aortic surgical and peripheral vascular grafts, thoracic drainage, surgery perfusion, extracorporeal life support, cardiac assist, endoscopic vessel harvesting systems, beating heart surgery products. The company also provides surgical tables and lamps, ceiling service units, wall modules, and hybrid operating rooms (OR); infection control products; integrated workflow solutions, including sterile supply management, patient flow optimization, and OR integration; and life science, such as sterilizers, cleaning and asepsis products, and isolators. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in Europe, the Middle East, Africa, the Americas, Asia, and Pacific. The company has a strategic partnership with Verb Surgical Inc. to develop digital surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.
About 21st North
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
Receive News & Ratings for GETINGE AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GETINGE AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.